Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NL-OMON47235
NL-OMON47235CompletedPhase 3

An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc; BIIB029) in the Prevention and Treatment of Bleeding in Previously Untreated Patients With Severe Hemophilia B - 998HB303, PUPs B

Bioverativ Therapeutics Inc.0 sites5 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 3
Status
Completed
Enrollment
5
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
2 to 17 (—)

Inclusion Criteria

  • •1. Ability of the subject or their parent or legal guardian to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (PHI) or equivalent, and/or to provide assent in accordance with national and local regulations.;2. Male, age <18 years at the time of informed consent.;3. Weight *3.5 kg at the time of informed consent.;4. Severe hemophilia B defined as *2 IU/dL (*2%) endogenous FIX documented in the medical record or as tested during the Screening Period. Any subject who is enrolled based on results of the local laboratory must be withdrawn if the central laboratory screening results indicate a baseline FIX activity level >2% of normal.

Exclusion Criteria

  • •1. History of positive inhibitor testing. A prior history of inhibitors is defined based on a patient's historical positive inhibitor test using the local laboratory Bethesda value for a positive inhibitor test (i.e. equal to or above lower limit of detection).
  • •2. History of hypersensitivity reactions associated with any rFIXFc administration.
  • •3. Exposure to blood components or injection with a FIX concentrate (including plasma derived) other than rFIXc.
  • •4. Injection with commercially available rFIXFc more than 28 days prior to Screening.
  • •5. More than 3 injections of commercially available rFIXFc prior to confirmation of eligibility.
  • •6. Other coagulation disorder(s) in addition to hemophilia B.
  • •7. Any concurrent clinically significant major disease that, in the opinion of the Investigator, would make the subject unsuitable for enrollment (e.g., HIV infection with CD4 lymphocyte count <200 cells/µL or a viral load > 200 particles/µL, or any other known congenital or acquired immunodeficiency).
  • •8. Current systemic treatment with chemotherapy and/or other immunosuppressant drugs. Use of steroids for treatment of asthma or management of acute allergic episodes or otherwise life-threatening episodes is allowed. Treatment in these circumstances should not exceed a 14-day duration.
  • •9. Participation within the past 30 days in any other clinical study involving investigational treatment.
  • •10. Current enrollment in any other clinical study involving investigational treatment.
  • •11. Inability to comply with study requirements.
  • •12. Other unspecified reasons that, in the opinion of the Investigator or Bioverativ, make the subject unsuitable for enrollment.

Investigators

Similar Trials

Active, not recruiting
Phase 1
A clinical study involving previously untreated patients with haemophilia A to look at how safe an experimental replacement factor VIII protein (known as rFVIIIFc) is to take and how well it works to prevent and stop bleeds.MedDRA version: 17.0 Level: LLT Classification code 10053753 Term: Hemophilia A without inhibitors System Organ Class: 100000004850MedDRA version: 17.0 Level: LLT Classification code 10060612 Term: Hemophilia A System Organ Class: 100000004850Hemophilia A
EUCTR2013-005512-10-ESBiogen Idec Research Ltd125
Withdrawn
Phase 3
An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) in the Prevention and Treatment of Bleeding in Previously Untreated Patients With Severe Hemophilia A1006447710005330Hemophilia AHemophilia
NL-OMON45745Bioverativ Therapeutics Inc.4
Active, not recruiting
Phase 1
A clinical study involving previously untreated patients with haemophilia A to look at how safe an experimental replacement factor VIII protein (known as rFVIIIFc) is to take and how well it works to prevent and stop bleeds.Hemophilia A
EUCTR2013-005512-10-DKBiogen Idec Research Ltd125
Active, not recruiting
Phase 1
A clinical study involving previously untreated patients with haemophilia B to look at how safe an experimental replacement factor IX protein (known as rFIXFc) is to take and how well it works to prevent and stop bleeds.Hemophilia B (congenital coagulation factor IX [FIX] deficiencyChristmas disease) is an X-linked bleeding disorder that occurs predominantly in males, characterized by a deficiency of functional FIX.MedDRA version: 20.1 Level: LLT Classification code 10053754 Term: Hemophilia B without inhibitors System Organ Class: 100000004850
EUCTR2013-003629-27-IEBioverativ Therapeutics Inc.35
Active, not recruiting
Phase 1
A clinical study involving previously untreated patients with haemophilia B to look at how safe an experimental replacement factor IX protein (known as rFIXFc) is to take and how well it works to prevent and stop bleeds.Hemophilia B (congenital coagulation factor IX [FIX] deficiencyChristmas disease) is an X-linked bleeding disorder that occurs predominantly in males, characterized by a deficiency of functional FIX.MedDRA version: 16.1Level: LLTClassification code 10053754Term: Hemophilia B without inhibitorsSystem Organ Class: 100000004850
EUCTR2013-003629-27-ITBiogen Idec Research Ltd33